Karyopharm Therapeutics

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Oct. 1, 2026 NEWTON, Mass. , Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics In

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates Yahoo Finance

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Sept. 1, 2026 NEWTON, Mass. , Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis PR Newswire NEWTON, Mass., Aug. 31, 2026 – sNDA Submitted un

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission PR Newswire NEWTON, Mass., Aug. 13, 2026 – Planned August sNDA Submis

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates Yahoo Finance

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 PR Newswire NEWTON, Mass., Aug. 10, 2026 -- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET --

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway PR Newswire NEWTON, Mass., July 30, 2026 – Company Plans to Submit sNDA in August

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer PR Newswire NEWTON, Mass., July 30, 2026 – The Trial Did Not Meet the Primary Endpoint of Progression-Free

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock? Yahoo Finance

Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update Yahoo Finance

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 PR Newswire NEWTON, Mass., June 3, 2026 NEWTON, Mass. , June 3, 2026 /PRNewswire/ -- Karyopharm

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 PR Newswire NEWTON, Mass., June 2, 2026 – New Data will Hig

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of C

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation PR Newswire NEWTON, Mass., June 1, 2026 – Eve

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass., May 28, 2026 NEWTON, Mass. , May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasda